Figure 5.

Visual acuity changes during the treatment course. The patient underwent craniotomy with tumor removal in June 2014. Her visual acuity only improved to 0.7 LogMAR in the following 2 months. She was then administered pulse methylprednisolone at 500 mg/d for 3 days, 500 mg of intravenous rituximab every 2 weeks (for a total of 2 doses), and 500 mg of intravenous pulse cyclophosphamide every month (for a total of 3 doses). The dose of prednisolone was kept at 10 mg/d for maintenance therapy. Two months after the initiation of immunosuppressive therapy, her BCVA returned to 0.1 LogMAR. The serum IgG4 also decreased after the initiation of immunosuppressive therapy.